Iron metabolism and management: focus on chronic kidney disease
- 1 April 2021
- journal article
- research article
- Published by Elsevier in Kidney International Supplements
- Vol. 11 (1) , 46-58
Abstract
No abstract availableKeywords
Funding Information
- Johnson & Johnson Innovative Medicine
- FibroGen
- AstraZeneca
This publication has 107 references indexed in Scilit:
- Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesisJournal of Clinical Investigation, 2012
- Hypoxia-Inducible Factor-2α Mediates the Adaptive Increase of Intestinal Ferroportin During Iron Deficiency in MiceGastroenterology, 2011
- Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in miceHepatology, 2011
- Suppression of hepatic hepcidin expression in response to acute iron deprivation is associated with an increase of matriptase-2 proteinBlood, 2011
- Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRDJournal of the American Society of Nephrology, 2010
- Timing of Onset of CKD-Related Metabolic ComplicationsJournal of the American Society of Nephrology, 2009
- The Serine Protease Matriptase-2 (TMPRSS6) Inhibits Hepcidin Activation by Cleaving Membrane HemojuvelinCell Metabolism, 2008
- Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)Journal of Clinical Investigation, 2007
- Interleukin-6 induces hepcidin expression through STAT3Blood, 2006
- The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammationJournal of Clinical Investigation, 2002